Deal Watch: Orexigen And Takeda Call It Quits, AbbVie And Boehringer Join Forces
Executive Summary
AbbVie pays $595m up front for rights to Boehringer's Phase III anti-IL-23 candidate, which it sees as a potential competitor to Stelara. Merck and Sanofi end their European vaccines joint venture after a 22-year run.